Fig. 4From: Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic Myeloma Study GroupProportion of patients developing carfilzomib-dexamethasone (Kd) related symptoms during the study period for the Kd maintenance and the observation groupBack to article page